Government guidelines : Treatment protocols for different age groups

Protocol for management of child with COVID-19

Protocol for management of pregnant women with suspected symptoms of COVID-19


Protocol for management of adult with COVID-19


Key Updates to the Guidelines

Therapeutic Management of Adults With COVID-19

Updated to incorporate recommendations for when to use combination anti-SARS-CoV-2 monoclonal antibodies and tocilizumab (in combination with dexamethasone) in certain patients with COVID-19.

Overview of COVID-19

A new subsection has been added to discuss the emerging information on SARS-CoV-2 variants of concern.

Clinical Spectrum of SARS-CoV-2 Infection

A new subsection describes reports of SARS-CoV-2 reinfection in individuals who had previously documented COVID-19. The discussion on patients who experience persistent symptoms or organ dysfunction after acute COVID-19 has also been updated.

Anti-SARS-CoV-2 Monoclonal Antibodies

This section now incorporates information and recommendations from the Panel’s Statement on the Emergency Use Authorization of Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment of COVID-19 that was released on April 8, 2021. This section also includes information on the various reported SARS-CoV-2 variants and the potential impact of mutations on in vitro susceptibility to different anti-SARS-CoV-2 monoclonal antibodies.

Convalescent Plasma

High-titer convalescent plasma is available through a Food and Drug Administration Emergency Use Authorization for the treatment of certain hospitalized patients with COVID-19. This section has been updated to include new recommendations regarding the use of convalescent plasma in hospitalized patients with COVID-19 (including those who have impaired humoral immunity) and in nonhospitalized patients with COVID-19.

Interleukin-6 Inhibitors (With Focus on Tocilizumab)

Updated to incorporate and expand on the Panel’s statements on the use of tocilizumab for the treatment of COVID-19 that were released on February 3 and March 5, 2021. This section includes considerations for using tocilizumab in combination with dexamethasone in certain hospitalized patients who are exhibiting rapid respiratory decompensation due to COVID-19.

Special Considerations in Children

This section now includes expanded discussions on treatment considerations for children with acute COVID-19. Additions to the section include updated information on the epidemiology and risk factors for COVID-19 in children, vertical transmission of SARS-CoV-2 infection, and multisystem inflammatory syndrome in children (MIS-C).

Other Updates to the Guidelines

The following sections have been updated to include recommendations and special considerations for SARS-CoV-2 vaccination in specific populations:

The information in the following sections has also been updated:

Post a Comment

COVID 19

This is an initiative by Kanpur university to help people of Kanpur